Robert Wasserman
Stock Analyst at Benchmark
(2.66)
# 1,966
Out of 5,241 analysts
119
Total ratings
48.15%
Success rate
2.96%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Upgrades: Buy | $95 | $88.16 | +7.76% | 13 | Feb 20, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $67.12 | +34.09% | 11 | Feb 19, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $175 → $220 | $213.21 | +3.18% | 12 | Nov 7, 2025 | |
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $72.01 | -23.62% | 7 | Nov 3, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $100 → $38 | $4.63 | +709.94% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $43.30 | +73.21% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $7.71 | +94.55% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $2.18 | +175.23% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $41.71 | -16.08% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $4.09 | - | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $20.76 | +44.51% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $3.13 | +59.74% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $7.94 | +51.13% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.46 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $102.87 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.03 | -0.74% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $100 | $2.96 | +3,278.38% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.41 | +3,012.03% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $161.91 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $438.34 | +32.32% | 1 | Jul 16, 2021 |
Integer Holdings
Feb 20, 2026
Upgrades: Buy
Price Target: $95
Current: $88.16
Upside: +7.76%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Buy
Price Target: $75 → $90
Current: $67.12
Upside: +34.09%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $175 → $220
Current: $213.21
Upside: +3.18%
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $72.01
Upside: -23.62%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $100 → $38
Current: $4.63
Upside: +709.94%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $43.30
Upside: +73.21%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $7.71
Upside: +94.55%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $2.18
Upside: +175.23%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $41.71
Upside: -16.08%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.09
Upside: -
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $20.76
Upside: +44.51%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $3.13
Upside: +59.74%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $7.94
Upside: +51.13%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.46
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $102.87
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.03
Upside: -0.74%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $100
Current: $2.96
Upside: +3,278.38%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.41
Upside: +3,012.03%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $161.91
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $438.34
Upside: +32.32%